A Phase 1, Single Centre, Dose-escalating, Placebo-controlled Study of a Genetically Modified B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs BPZE 1 (Primary)
- Indications Pertussis
- Focus Adverse reactions
- 19 Feb 2016 Results published in the journal PLOS One, according to an ILiAD Biotechnologies media release.
- 30 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.